Quantitative echo contrast concentration measurement by Doppler sonography

A fundamental study for quantitative measurement of ultrasound contrast concentration by low mechanical index contrast ultrasonography

PURPOSE

In high mechanical index (MI) contrast ultrasonography it has been shown that the power of contrast signal intensity (CI) has a strong linear correlation with the concentration of the ultrasound contrast agent under conditions of constant applied acoustic pressure. However, it is unclear whether the linearity is preserved in low-MI contrast ultrasonography. Thus, we investigated the relationship between ultrasound contrast concentration and CI in vitro.

METHODS

Solutions of the ultrasound contrast agents Definity and Imagent were prepared at concentrations of 0.5, 2, 8, 32, and 128 μl/l. Placing a jelly block between the transducer and the solution, the solutions were transmitted using pulse subtraction imaging with an MI of 0.05, 0.1, and 0.5. CI was measured in dB in a region of interest 3 mm in height placed just below the border between the jelly and the solution. Data were plotted using double logarithm scales, where the concentration was expressed in dB as 10 × log (concentration).

RESULTS

CI in dB had a strong linear correlation with concentration in dB for both agents with any MI. Best fitted slopes were close to 1, indicating that the power of CI is proportional to the concentration.

CONCLUSIONS

In low-MI contrast ultrasonography, the power of CI is proportional to contrast concentration, and CI in dB is logarithmic to the concentration. Thus, the microbubble concentration can be quantitatively measured even in low-MI contrast ultrasonography.

Trends in myocardial contrast echocardiography: parameteric versus volumetric imaging

It is now possible to perform myocardial contrast echocardiography at the bedside with an intravenous injection of commercially available contrast media. Although myocardial contrast echocardiography is a sensitive method for the detection of coronary stenosis and myocardial viability, its diagnosis has relied largely on the subjective interpretation of regional perfusion by experienced clinicians. Thus, quantification of myocardial contrast echocardiography data and displaying comprehensive images have been necessary for its routine application. In this review, new methods for quantifying or displaying myocardial contrast echocardiography parameters will be introduced: firstly, parametric imaging that displays the parameters of myocardial blood volume, blood flow velocity and myocardial blood flow separately; and secondly, color-coded maps of myocardial blood volume established from one myocardial contrast echocardiography image. These quantitative techniques can provide comprehensive and easy-to-understand images, although the quality of the baseline image remains a critical factor.

Correlation and agreement between contrast-enhanced ultrasonography and perfusion computed tomography for assessment of liver metastases from endocrine tumors: normalization enhances correlation

We studied correlation and agreement between perfusion parameters derived from contrast-enhanced ultrasonography (CEUS) and computed tomography (CT). Both techniques were performed in 16 patients with proven liver metastases from endocrine tumor. Replenishment study after ultrasound-induced destruction of microbubbles was used for CEUS quantification. CEUS-derived relative values of blood flow, blood volume and mean transit time were compared with perfusion CT-derived parameters measured in the same tumors. Significant correlation was observed between CEUS normalized values and CT absolute tumor values for blood flow (r = 0.58; p = 0.018), blood volume (r = 0.61; p = 0.012) and mean transit time (r = 0.52; p = 0.037). Correlation was not significant for non-normalized values. Agreement between CEUS normalized values and perfusion CT relative values was significant (p < 0.04). Estimated bias between CEUS and CT for relative perfusion values was -1.38 (-5.02; 2.27) for blood flow, +0.26 (-0.79; 1.31) for blood volume and +0.21 (-0.46; 0.87) for mean transit time. We conclude that normalization markedly increased correlation between CEUS- and CT-derived perfusion values and allowed agreement assessment.

Effects of acoustic insonation parameters on ultrasound contrast agent destruction

Ultrasound contrast agents (UCAs) are used to enhance the acoustic backscattered intensity of blood and thereby assist the assessment of blood perfusion. Characterization of UCA destruction provides important information for the design of contrast-assisted perfusion imaging. High-speed optical observation of single microbubble destruction during acoustic insonation has been performed in previous studies. The results identified that pressure, center frequency and transmission phase have significant effects on the fragmentation threshold. We proposed an acoustic-based experiment method to demonstrate the relationship between different acoustic exposure conditions and the degree of UCA destruction. The method also provides a simple and convenient way to determine the microbubble destruction threshold. The experiments introduced three insonation parameters, including acoustic pressure (0 to 1 MPa), pulse frequency (1, 2.25, 5 and 7.5 MHz) and pulse length (1 to 10 cycles). The term of surviving percentage (SP) was proposed to represent the ratio of UCA backscattered power with and without acoustic insonation. The results showed that the SP decreased with decreasing pulse frequency, but with increasing transmission acoustic pressure and pulse length. In addition, there was an exponential relationship between SP and acoustic pressure, and thus the UCA destruction pressure threshold could be predicted from the fitted exponential curve. The results also show that the degree of UCA destruction was not related to mechanical index (MI). Potential applications of this method include UCA high-resolution destruction/replenishment imaging model, microbubble cavitation, sonoporation in drug delivery and gene therapy.

Feasibility exploration of blood flow estimation by contrast-assisted Nakagami imaging

The microbubble contrast agent destruction/replenishment technique has been widely applied to ultrasound-based blood flow estimation. The rate of increase of the time-intensity curve (TIC) due to microbubbles flowing into the region of interest as measured from B-mode images closely reflects the flow velocity. In this study, we monitored microbubble replenishment by a proposed new approach called the time-Nakagami-parameter curve (TNC) obtained from Nakagami-parameter images for quantifying the flow velocity. The feasibility of using the TNC to estimate the flow was evaluated in computer simulations of the TIC and TNC for flow velocities from 10 to 30 cm/s under an ultrasound frequency of 5 MHz. The clutter effects on the TIC and TNC were explored in amore realistic situation by carrying out phantom measurements of 25 MHz. The rates of increase of the TIC and TNC were expressed by the rate constants beta1 and betaN of a monoexponential model, respectively. The average beta1 increased from 38 to 110 s(-1) as the flow velocity increased from 10 to 30 cm/s (r = 0.98), and the average betaN increased from approximately 40 to 120 s(-1) for the same increase in flow velocity (r = 0.98). The p-value between the results of beta1 and betaN as a function of flow velocity was 0.77. These results represent that betaN quantifies the flow velocity similarly to the conventional beta1. In particular, both the simulation and experimental results revealed that the TNC method conditionally tolerates the presence of nonperfused areas (e.g., surrounding tissues or vessel walls) in the region of interest without requiring application of an additional wall filter to cancel the influences of clutter echoes on the flow estimation. These findings suggest that the TNC-based technique may be a potential method as a complementary tool for the conventional TIC technique to improve the estimation of blood flow.

Diagnosis of liver cirrhosis by transit-time analysis at contrast-enhanced ultrasonography

PURPOSE

The aims of this prospective study were to evaluate analysis of sulfur-hexafluoride-filled microbubble contrast agent (Sonovue) transit times as a tool for differentiating liver cirrhosis from the noncirrhotic stage of liver disease and to compare its performance with that of conventional B-mode and Doppler ultrasonography (US).

MATERIALS AND METHODS

Contrast-enhanced hepatic ultrasonography with the US contrast agent Sonovue was performed on 38 patients with diagnoses of hepatic cirrhosis based on unequivocal clinical signs or liver biopsy findings (Child-Pugh classes A in 19, B in 16 and C in three), 31 patients with noncirrhotic diffuse liver disease (biopsy confirmed) and 14 controls without diffuse liver disease. Time curves of hepatic-vein signal intensity were analysed using objective criteria to determine the time of enhancement onset (hepatic-vein arrival time) and peak enhancement (hepatic-vein peak enhancement). Accuracy in diagnosing cirrhosis was compared with that based on B-mode and Doppler data.

RESULTS

Hepatic-vein arrival time in cirrhotic patients was significantly shorter (p < 0.01) than in noncirrhotic (chronic liver disease and controls) patients. Peak enhancement times in these three groups were not significantly different. An arrival-time cutoff of 17 s distinguished cirrhotic from noncirrhotic patients with high accuracy (100% sensitivity, 93.3% specificity, positive and negative predictive values 92.6% and 100%, respectively) and excellent reproducibility (kappa coefficients of 1.0 and 0.93 for intraand interobserver agreement). Contrast-enhanced US showed better sensitivity than the B-mode and Doppler data.

CONCLUSIONS

Analysis of the time of onset of US contrast enhancement of the hepatic vein appears to be a potentially useful noninvasive supplement to conventional sonography and Doppler in the follow-up of patients with chronic diffuse liver disease.

Contrast-enhanced ultrasound to evaluate the severity of chronic hepatitis C

BACKGROUND

Non-invasive techniques are being developed to assess the severity of liver disease. Haemodynamic changes in the hepatic circulation during the development of liver disease can be evaluated with contrast-enhanced ultrasound.

AIM

To evaluate the possible correlation between ultrasound contrast-agent transit times and different stages of chronic hepatitis C.

PATIENTS

Sixteen patients with clinically evident hepatitis C virus-related cirrhosis, 22 non-cirrhotic patients with chronic hepatitis C and 14 controls with no clinical evidence of liver disease were studied.

METHODS

Contrast-enhanced hepatic ultrasonography was performed with a sulphur hexafluoride-filled microbubble contrast agent, and time curves of hepatic vein signal intensity were analysed to determine the time of enhancement onset (hepatic vein arrival time) and peak enhancement (hepatic vein peak enhancement).

RESULTS

Hepatic vein arrival time in cirrhotic patients was significantly shorter (p<0.001) than in non-cirrhotic patients and controls. Within the group with chronic hepatitis C, METAVIR scores of fibrosis and necro-inflammatory changes had no significant effect on hepatic vein arrival times.

CONCLUSION

Analysis of the time of onset of ultrasound contrast enhancement of the hepatic vein appears to be a simple, non-invasive method for reliably excluding cirrhosis with signs of portal hypertension, but not for assessing the severity of either chronic hepatitis C or cirrhosis.

Novel quantitative assessment of myocardial perfusion by harmonic power Doppler imaging during myocardial contrast echocardiography

OBJECTIVE

To test the hypothesis that the power of the received signal of harmonic power Doppler imaging (HPDI) is proportional to the bubble concentration under conditions of constant applied acoustic pressure, and to determine whether a new quantitative method can overcome the acoustic field inhomogeneity during myocardial contrast echocardiography (MCE) and identify perfusion abnormalities caused by myocardial infarction.

METHODS

The relation between Levovist concentration and contrast signal intensity (CI) of HPDI was investigated in vitro under conditions of constant acoustic pressure. MCE was performed during continuous infusion of Levovist with intermittent HPDI every sixth cardiac cycle in 11 healthy subjects and 25 patients with previous myocardial infarction. In the apical views myocardial CI (CI(myo)) was quantified in five myocardial segments. The CI from the left ventricular blood pool adjacent to the segment was also measured in dB and subtracted from the CI(myo) (relative CI (RelCI)).

RESULTS

CI had a logarithmic correlation and the calculated signal power a strong linear correlation with Levovist concentration in vitro. Thus, a difference in CI of X dB indicates a microbubble concentration ratio of 10(X/10). In normal control subjects, CI(myo) differed between the five segments (p < 0.0001), with a lower CI(myo) in deeper segments. However, RelCI did not differ significantly between segments (p = 0.083). RelCI was lower (p < 0.0001) in the 39 infarct segments (mean (SD) -18.6 (2.8) dB) than in the 55 normal segments (mean (SD) -15.1 (1.6) dB). RelCI differed more than CI(myo) between groups.

CONCLUSIONS

The new quantitative method described can overcome the acoustic field inhomogeneity in evaluation of myocardial perfusion during MCE. RelCI represents the ratio of myocardium to blood microbubble concentrations and may correctly reflect myocardial blood volume fraction.

Myocardial contrast echocardiography with a new calibration method can estimate myocardial viabilityin patients with myocardial infarction

OBJECTIVES

We have developed a novel calibration technique applicable for myocardial contrast echocardiography (MCE). We assessed the value of this technique in the recognition of myocardial infarction (MI) and its spatial extent, and we also performed a validation study in normal subjects.

BACKGROUND

The heterogeneity of contrast intensity (CI) among myocardial segments limits the clinical use of MCE.

METHODS

We performed MCE with a slow-bolus injection of Levovist and recorded end-systolic harmonic power Doppler images at intervals of four heart beats in 15 normal volunteers and 30 patients with MI. We divided the left ventricular (LV) wall into 12 segments and placed the region of interest in the subendocardial region in each segment and in the adjacent LV cavity. We measured calibrated CI (dB) by subtracting the cavity CI from myocardial CI.

RESULTS

The mean intersegmental difference in myocardial CI was 15.8 dB at baseline, whereas it was reduced to 6.3 dB after calibration (p < 0.01). Calibrated CI was higher in the kinetic segments than in the akinetic segments (-14.5 +/- 2.3 dB [range -18.7 to -9.9 dB] vs. -22.5 +/- 2.6 dB [-27.8 to -17.7 dB], p < 0.001), and -18.0 dB was the optimal cutoff point to discriminate these from each other. Color-coded mapping of calibrated CI may identify the spatial extent of persistently akinetic myocardium as areas of calibrated CI of <or=-18.0 dB.

CONCLUSIONS

This new calibration method reduces the intersegmental difference in CI in normal subjects. Calibrated CI provides an estimate of persistently akinetic myocardium in patients with MI, and its color-coded mapping is comprehensive and identifies the spatial extent of MI.

Measurement of radial artery contrast intensity to assess cardiac microbubble behavior

OBJECTIVES

We sought to determine whether analysis of the contrast signal from the radial artery is better able to reflect changes in left ventricular (LV) microbubble dynamics than the signal from the LV itself.

BACKGROUND

Assessment of microbubble behavior from images of the LV may be affected by attenuation from overlying microbubbles and nonuniform background signal intensities. The signal intensity from contrast in a peripheral artery is not affected by these artifacts and may, thus, be more accurate.

METHODS

After injection of a contrast bolus into a peripheral vein, signal intensity was followed simultaneously in the LV and radial artery. The measurements were repeated using continuous, triggered, low and high mechanical index harmonic imaging of the LV.

RESULTS

Peak and integrated signal intensities ranged from 25 dB and 1550 dB/s, respectively, with radial artery imaging to 5.6 dB and 471 dB/s with ventricular imaging. Although differences in microbubble behavior during the different imaging protocols could be determined from both the LV and radial artery curves, analysis of the radial artery curves yielded more consistent and robust differences.

CONCLUSIONS

The signal from microbubbles in the radial artery is not affected by shadowing and is, thus, a more accurate reflection of microbubble behavior in the LV than the signal from the LV itself. This may have important implications for the measurement of myocardial perfusion by contrast echocardiography.

The role of ultrasound in molecular imaging

Ultrasound has received less attention than other imaging modalities for molecular imaging, but has a number of potential advantages. It is cheap, widely available and portable. Using Doppler methods, flow information can be obtained easily and non-invasively. It is arguably the most physiological modality, able to image structure and function with less sedation than other modalities. This means that function is minimally disturbed, and multiple repeat studies or the effect of interventions can easily be assessed. High frame rates of over 200 frames a second are achievable on current commercial systems, allowing for convenient cardiac studies in small animals. It can be used to guide interventional or invasive studies, such as needle placement. Ultrasound is also unique in being both an imaging and therapeutic tool and its value in gene therapy has received much recent interest. Ultrasound biomicroscopy has been used for in utero imaging and can guide injection of virus and cells. Ultrahigh frequency ultrasound can be used to determine cell mechanical properties. The development of microbubble contrast agents has opened many new opportunities, including new functional imaging methods, the ability to image capillary flow and the possibility of molecular targeting using labelled microbubbles.

Transfer function analysis of ultrasonic time-intensity measurements

Time-intensity measurements of ultrasonic-contrast microbubbles based on the dilution theory have been used to assist blood flow estimation. The compartment model has been employed to describe the dilution process. Under the linear and time-invariant assumption, the time-intensity curve measured at the output of a compartment (i.e., blood mixing chamber) is the convolution of the input time-intensity curve with the compartment's transfer function. Thus, transfer function analysis is possible using deconvolution when the temporal variations in both the input and the output intensities are available. Note that the linear and time-invariant assumption requires a constant flow rate because, with flow pulsation, the flow rate changes with time and the mixing process becomes time varying. Thus, the purpose of this paper was to study the effects of flow pulsation on time-intensity measurements. In addition, a deconvolution technique based on a recursive least squares approach is used for transfer function analysis. Both simulations and experiments were performed; the results from which indicate that the pulsation generally does not affect the validity of time-intensity-based flow estimation. The proposed deconvolution technique is also effective for both constant and pulsatile flows; thus, permitting transfer function analysis in various flow conditions. One potential application of this transfer function analysis is to remove the effects of a noninstantaneous input function. The results from this paper lead to future work in brain-perfusion estimation based on extracranial time-intensity measurements.

Value of contrast-enhanced power Doppler sonography using a microbubble echo-enhancing agent in evaluation of small breast lesions

PURPOSE

The purpose of this study was to prospectively evaluate the usefulness of contrast-enhanced power Doppler sonography (PDUS) using a microbubble echo-enhancing agent in differentiating between malignant and benign small breast lesions.

PATIENTS AND METHODS

Between July 1, 2000, and September 30, 2001, we performed gray-scale sonographic examination of patients in whom diagnostic sonography or screening mammography had revealed solid breast lesions measuring less than 2 cm in the largest dimension. The patients were then examined on PDUS before and after injection of a microbubble contrast agent. The sonographic findings for all 3 techniques, as well as the morphologic features of the Doppler signals for each patient before and after injection of the contrast agent on PDUS, were independently assessed. Each lesion was classified as "benign" or "malignant" on the basis of specific criteria for sonographic interpretation. A hemodynamic study was performed in which time-transit profiles of the Doppler signals on contrast-enhanced PDUS were generated using a computer-assisted program, and the results for each patient were compared with the findings of a histopathologic examination of surgical specimens.

RESULTS

Thirty-six patients (35 women and 1 man) with a mean age of 43.5 years (range, 18-69 years) were evaluated. The tumors ranged from 4 to 19 mm in the largest dimension. Histopathologic examination revealed that 19 tumors were benign and 17 were malignant. For morphologic diagnosis of the malignant lesions, the sensitivity of gray-scale sonography was 100%, compared with 29% for PDUS without contrast enhancement. The specificity of gray-scale sonography was 47%, compared with 74% for PDUS without contrast enhancement. Contrast-enhanced PDUS had a sensitivity of 71% and a specificity of 58%. The diagnostic accuracy was 72% for gray-scale sonography, 53% for PDUS without contrast enhancement, and 64% for contrast-enhanced PDUS. The time-transit profiles of the hemodynamic study did not reveal a statistically significant difference in the accuracy rates of contrast-enhanced PDUS between benign and malignant breast lesions.

CONCLUSIONS

Compared with PDUS without contrast enhancement, contrast-enhanced PDUS provides better visualization of the morphology of vascular Doppler signals that is characteristic of malignancy and therefore has a higher sensitivity and diagnostic accuracy, albeit a lower specificity. In differentiating between benign and malignant small breast lesions, contrast-enhanced PDUS can be helpful when used with gray-scale sonography and PDUS without contrast enhancement.

The effect of echo contrast agent on Doppler velocity measurements

The purpose of this investigation was to determine the effect of echo contrast agents on spectral Doppler velocity measurements. SH U 508A was administered by IV injection in 15 patients. The transmitral flow velocity was measured at the E- and A-wave peaks before the start and at the peak of the contrast effect. The Doppler velocity was determined from the Doppler video spectral display and from power spectral analysis of the audio Doppler signal. The Doppler signal intensity was also measured. The Doppler signal intensity increased 17.4 +/- 3.5 dB (p < 0.0001) following echo contrast injection. This was associated with a significant increase in the spectral peak velocity as determined from either the video display or audio analysis. (p < 0.0001). The velocity corresponding to the audio power peak frequency (the modal velocity) did not change significantly (p = NS) and was independent of Doppler signal strength.

Functional ultrasound methods in oncological imaging

The real time nature of ultrasound and functional methods such as Doppler ultrasound mean that ultrasound can claim to have always been a functional imaging method, but recent developments in quantitation, dramatic improvement in Doppler performance and now microbubbles have created many exciting new applications. These include methods for assessing the neovascularity of tumours, for following the effects of therapy and for predicting the likelihood of development of metastatic disease at the staging of primary tumours.

A review of physical phenomena associated with ultrasonic contrast agents and illustrative clinical applications

Successful clinical applications of contrast agents involve an understanding of the physical interaction of ultrasound (US) with contrast agents. This paper reviews the physical phenomena involved in these interactions and discusses the relevant theoretical background for modeling US-contrast agent interactions. Measurement techniques using US to obtain information regarding contrast agents are summarized. Illustrative clinical applications are given in the second part of the paper. Recent developments in nonlinear imaging techniques and transient techniques are reviewed. New methods, such as depletion perfusion measurement, and high-frequency applications are included.

Time-intensity-based volumetric flow measurements: an in vitro study

Ultrasonic contrast agents have been used to assist blood flow measurements. Several contrast-specific flow measurement techniques have been proposed during the last few years. Among them, a method based on relative enhancement of the backscattered signal as a function of time is of particular interest. This method is also known as the time-intensity method. The method is based on the indicator-dilution theory, and the time-intensity curve is used to derive blood flow-related parameters such as the flow rate and the blood mixing volume. Previous in vitro studies done by other research groups were mainly based on a perfusion model or an artery model. Results showed that several parameters derived from the time-intensity curve had a good correlation with the flow rate under certain conditions. However, the studies did not focus on factors such as mixing volume, mixing chamber configuration and different types of mixing chamber. In this paper, dependence of the time-intensity curve is further studied. Specifically, two types of blood-mixing chambers were constructed. One was a spherical compartment phantom with two different sizes (260 and 580 mL) and different inflow/outflow configurations. The other was a perfusion phantom consisting of dialysis cartridges with the volume ranging from 114 to 351 mL. The time intensities were also measured at both the input and the output of the mixing chamber. A commercial agent (Levovist) and a self-made, albumin-based agent were used and the wash-out time constant and the mean transit time were derived for flow rates ranging from 500 to 1300 mL/min. For the perfusion phantom, results showed that the parameters had a good correlation with both the flow rate and the mixing volume. Results from the compartment phantom, on the other hand, indicated that the inflow/outflow configuration and the mixing size significantly affected the derived time constants. Potential applications of new volumetric flow estimation techniques based on both input and output intensities were also discussed.

Enhancement characteristics of the microbubble agent Levovist: reproducibility and interaction with aspirin

We investigated the reproducibility of Doppler enhancement indices following intravenous bolus injections of Levovist (Schering AG, Berlin) microbubbles. We also aimed to determine whether observations from animal studies suggesting that aspirin potentiates microbubble enhancement were reproducible in humans. In five healthy volunteers, time enhancement profiles of Doppler intensity following repeated bolus injections of Levovist were acquired from the common carotid artery, hepatic vein and kidney using spectral and power Doppler before and after oral aspirin (600 mg). Peak enhancement (PE), area under the curve (AUC) and decay slopes (lambda) were calculated. Hepatic vein contrast arrival time (AT) was determined subjectively. Well-defined carotid enhancement was seen in 19/20 injections. Reproducibility was high (r > 0.8). PE and AUG were unaffected by aspirin, but lambda was slightly reduced (P = 0.02). Renal power Doppler profiles were well defined (10/10) with no significant changes of AUC, PE or lambda after aspirin. Our study demonstrates good reproducibility of carotid spectral Doppler time intensitometry with Levovist in man. Aspirin does not have a significant effect on enhancement indices except carotid spectral Doppler decay. We conclude that aspirin is unlikely to potentiate microbubble enhancement, as seen in animal studies.

Quantitative and qualitative analysis of in vivo Doppler signal enhancement of FS-069

RATIONALE AND OBJECTIVES

In vivo lifetime of ultrasound (US) contrast agents is still limited and thus a cause for ongoing investigations of new substances. The purpose of this study was to determine the time intensity changes of the Doppler signals obtained within the femoral vein after two different doses of a new microsphere-based ultrasound contrast agent.

METHODS

Twenty-four healthy male volunteers (mean age, 29; average weight, 76 kg) were included in this study. All underwent a triplex Doppler US examination after an intravenous bolus injection of 0.3 mL and 1.0 mL Optison. To examine the signal enhancement characteristics of this contrast agent the audio signal of the pulsed-wave spectral Doppler US was measured quantitatively using an audio analyzer, whereas velocity-encoded color Doppler examinations were scored qualitatively (score 0-3).

RESULTS

The mean maximal enhancement of the audio signal at a dose of 1.0 mL FS-069 was significantly higher than with a bolus of 0.3 mL FS-069 (29 +/- 2 dB vs. 26 dB +/- 2 dB, P < 0.001). The time-intensity curves after each bolus injection yielded an early peak (one minute after the injection) followed by constantly decreasing signal intensities. The scoring of the velocity-encoded color Doppler US revealed an optimal enhancement (score 2) for 3 minutes and 20 seconds (0.3 mL Optison) and for 6 minutes (1.0 mL Optison), respectively.

CONCLUSIONS

This study showed the capability of triplex Doppler ultrasound signal enhancement after Optison. 1.0 mL Optison proved to be the more appropriate dose for an optimal signal enhancement than 0.3 mL Optison.

Techniques for perfusion imaging with microbubble contrast agents

The acoustic properties of ultrasound contrast agents vary widely with agent composition and insonation conditions. For contrast imaging, methods are required to match RF and Doppler processing to each combination of transmission parameters and agent and tissue properties. We propose a method that uses the measured or modeled echoes from agent and tissue to specify directly the characteristics of RF and Doppler filters for contrast imaging. The proposed method is sufficiently general to cover most common imaging techniques including harmonic greyscale, Doppler, and pulse inversion imaging. Using this method, sample filters were designed to detect myocardial perfusion with the contrast agent Optison (Mallinckrodt Medical, St. Louis, MO) under selected imaging conditions. Simplified power Doppler filtering, using a weighted sum of the Doppler samples, matched the performance of more complicated matrix filters. By coordinating the selection of RF and Doppler filters rather than designing these filters sequentially, agent-to-tissue contrast was increased by up to 3.9 dB. Under some conditions, fundamental RF filtering outperformed harmonic filtering for intermittent Doppler imaging.

Quantification of ultrasound contrast agent response: comparison of continuous wave Doppler and power Doppler to backscattered radiofrequency data

Our goal was to compare two quantification methods of ultrasound contrast agents available in clinical practice [continuous wave Doppler intensity (CWDI) and power Doppler intensity (PWDI)] to the reference technique (radio-frequency analysis) with a simple recirculating flow phantom using a renal dialysis cartridge. Measurements were made at different doses of perflenapent emulsion and BR1. Cineloops of power Doppler images were recorded using a clinically available ultrasound unit (HDI 3000). Simultaneously, integrated backscatter (IBS) was measured by analysis of radiofrequency signals, whereas Doppler signal intensity was measured with a continuous wave Doppler device. A linear relationship was found between CWDI and IBS and between PWDI and IBS when R(2) was calculated for each pair of parameters injection-by-injection. Results are summarized by the average R(2) for all injections between CWDI and IBS (BR1: R(2) = 0.93 +/- 0.05, perflenapent emulsion: R(2) = 0.94 +/- 0.03) and between PWDI and IBS (BR1: R(2) = 0.88 +/- 0.07, perflenapent emulsion: R(2) = 0.79 +/- 0.09). However, for all data obtained from all different injected doses and for both contrast agents, there was considerable variation of CWDI and PWDI values measured for a given value of IBS. In conclusion, for a fixed microbubble population, CWDI and PWDI can be proposed for quantification of USCA. However, their important variations observed at each dose make it difficult to link a single value of PWDI or CWDI or IBS to a single microbubble distribution composition.

Feasibility study of time-intensity-based blood flow measurements using deconvolution

Ultrasonic contrast agents have been used to enhance the acoustic backscattered intensity of blood and to assist the assessment of blood flow parameters. One example is the time-intensity method based on the indicator-dilution theory. In this case, a mixing chamber model can be employed to describe the concentration of the contrast agent as a function of time. By measuring the time intensities at both the input and output of the blood mixing chamber, blood flow information can be obtained if proper deconvolution techniques are applied. Note that most deconvolution techniques assume a linear and time invariant (LTI) system for the mixing of the contrast agent with blood. In this paper, the hypothesis that a blood mixing chamber is an LTI system was tested. Several aspects were studied. One aspect was the linear relationship between the concentration of the contrast agent and the backscattered intensity. The other aspect was the dependence of the derived time constants on the concentration. The concept of an effective mixing volume was also introduced and evaluated. Finally, the input and the output time constants were measured and compared to theory under the LTI assumption. Extensive experiments were performed. Two in vitro flow models were constructed and two contrast agents were used. Results indicated that the LTI assumption does not hold and quantitative flow estimation is generally not possible. Nonetheless, the indicator-dilution theory can still be applied if only relative measurements of the flow rate are required.

Infusion versus bolus of an ultrasound contrast agent: in vivo dose-response measurements of BR1

RATIONALE AND OBJECTIVES

To determine the efficacy of an ultrasound contrast agent infusion using Doppler intensitometry estimation of backscatter enhancement in blood.

METHODS

Multiple intravenous injections of BR1 (SonoVue) were performed in chronic dog studies, using bolus (0.05-2 mL) and infusion (3-40 mL/h during 6 minutes) administration. The pulsed Doppler signal from the femoral artery was recorded and analyzed for mean Doppler power and integrated fractional enhancement.

RESULTS

For bolus injection, time-intensity curves exhibited a rapid first pass (peak 30 dB for 0.45 mL) followed by a slower washout. Integrated fractional enhancement exhibited a linear relation with the dose (R2 = 0.99). For infusion administration, peak enhancement increased with the infusion rate from 8 to 22 dB. At rates exceeding 30 mL/h, the enhancement was stable with a plateau-like pattern.

CONCLUSIONS

Infusion of BR1 is easily achieved and allows the duration of enhancement to be increased as long as desired. Stable enhancement is obtained for rates greater than 30 mL/h.

Diagnosis and grading of intrapulmonary vascular dilatation in cirrhotic patients with contrast transesophageal echocardiography

BACKGROUND/AIMS

The use of transesophageal contrast echocardiography (TOCE) in the diagnosis of intrapulmonary vascular dilatation (IVD) and hepatopulmonary syndrome (HPS) needs to be studied. We tested the specificity of TOCE using traditional criteria and the value of a new method based on TOCE, a grading scale and a selected contrast.

METHODS

1) Several solutions were tested and two were selected: 20% mannitol and 0.9% saline. 2) 71 cirrhotic patients and 20 controls were studied. Left atrium opacification with contrast was classified into 6 degrees by TOCE. Mild and significant IVD were considered in relation to results in controls. Patients were studied with saline and mannitol-TOCE. Results were compared to transthoracic contrast echocardiography (TTCE), to gas exchange abnormalities and to Child class.

RESULTS

The reproducibility of TOCE grading was excellent, (Kappa >0.9). IVD detection using TTCE, mannitol-TOCE and saline-TOCE was 29.5%, 55% (25% mild and 30% significant), and 45% (38% mild and 7% significant), respectively. The best agreement with TTCE (reference method) was obtained with mannitol-TOCE, using significant IVD as the cut point. By this criterion, 18% reached the criteria of HPS using TTCE and 22% using mannitol-TOCE. Patients with IVD by TTCE had non-significant changes in gas exchange determinations. Patients with significant IVD by saline TOCE had lower mean PaO2 levels (67.3+/-14 vs. 79.5+/-11 mm Hg, p<0.05) than patients without IVD. Patients with significant IVD by mannitol TOCE had higher mean AaPO2 (29.3+/-14 vs. 19.7+/-9 mm Hg; p<0.005) and lower mean PaCO2 levels (30.1+/-4.4 vs. 33.4+/-4.8 mm Hg; p<0.05) than patients without IVD. Severity of IVD by TOCE correlated to Child class (r = 0.43; p<0.001).

CONCLUSIONS

The presence of contrast in the left atrium cannot be a criterion of IVD when TOCE is used. Our semi-quantitative scale has proved to be feasible and reproducible, presenting a good agreement with TTCE, and has shown better correlation with gas exchange abnormalities and Child class. Saline TOCE appears to be more specific in the detection of hypoxemic patients with IVD, but mannitol TOCE adds sensitivity.

Sonographic investigation of flow patterns in the perfused human placenta and their modulation by vasoactive agents with enhanced visualization by the ultrasound contrast agent Albunex

PURPOSE

Our objective was to demonstrate sonographically the flow distribution in the circulation of human placentae as well as the sensitivity of the human fetal capillary bed to vasoconstriction and dilatation.

METHODS

Five human full-term placental lobules were maintained in vitro with fetal and maternal flow. Commercial ultrasound scanners were used for imaging. Albunex (1 ml bolus) was administered to the fetal "artery" to monitor patterns of flow. U46619 (1 ml, 10(-6) M; a thromboxane agonist and potent vasoconstrictor) and/or nitroglycerin (a potent vasodilator) were added to the fetal artery.

RESULTS

Following the addition of U46619, mean "fetal pressures" rapidly rose from 23.2 +/- 0.8 to 118 +/- 2. 9 mm Hg (mean +/- standard error of mean; p < 0.001); venous flow rates decreased. As demonstrated by color Doppler imaging, flow markedly changed from a pattern of general distribution throughout the lobule to flow only near the chorionic plate. Color persistence was 94.4 +/- 6.5 seconds with Albunex after nitroglycerin and 39.8 +/- 3.4 seconds with Albunex after injection of U46619 (p < 0.001). Nitroglycerin had no effect when injected by itself but returned "constricted" flow to a "normal" pattern when injected after U46619.

CONCLUSIONS

The contrast medium Albunex improved visualization of the fetal circulation throughout the lobule. Flow in the human placental capillary bed can be regionally manipulated throughout the placental lobule by vasomodulators and monitored by Albunex-enhanced sonographic examination.

In vivo kinetics of microbubbles of SH U 508 A (Levovist): comparison with indocyanine green in rabbits

The aim of this study was to evaluate in vivo kinetics of microbubbles of SH U 508 A, in comparison with Indocyanine Green, a dye used as an indicator of blood flow. Microbubble kinetics were evaluated in various vessels (i.e., vena cava, aorta, renal artery, renal vein and portal vein) in rabbits after injection of SH U 508 A by measuring Doppler signals (n = 5). The kinetics of Indocyanine Green were evaluated by measuring absorbance using a photodiode (n = 5). Test substances (SH U 508 A 300 mg/mL and Indocyanine Green 1.25 mg/mL) were injected IV at a dose of 0.1 mL/kg B.W. Peak signal intensity was observed immediately after injection of SH U 508 A, followed by biphasic decay. The rates of biphasic decay were similar in all vessels. A second peak of the signal, which indicated recirculation of the microbubbles, was observed in the vena cava. The circulation and recirculation times of the microbubbles after injection of SH U 508 A were similar to that of Indocyanine Green. These findings suggest that the majority of SH U 508 A microbubbles circulate through the body similarly to blood flow, without retention, in the vasculature.

Effect of filling gases on the backscatter from contrast microbubbles: theory and in vivo measurements

Two surfactant-based contrast agents, ST44 and ST68, were produced according to US Patent # 5,352,436 and filled with either air, C4F10 (perfluorobutane) or SF6 (sulfur hexaflouride). Ten rabbits received i.v. injections of each agent/gas combination with 5 repetitions of each dose (range: 0.005-0.13 mL/kg). A custom-made 10-MHz cuff transducer was placed around the surgically exposed distal aorta and audio Doppler signals were acquired in vivo. Quantitative in vivo dose responses were calculated off-line using spectral power analysis and compared to a theoretical model of microbubble dissolution and enhancement. For qualitative comparisons, 10 rabbits were imaged pre- and postcontrast administration (dose: 0.1 mL/kg) in gray-scale and colour. All agent/gas combinations produced marked Doppler enhancement with air bubbles enhancing least of all (p < 0.0001) and ST68-SF6 best of all (maximum: 27.6 +/- 2.04 dB; p < 0.012). There were no significant differences between other agent/gas combinations (0.30 < p < 0.70). Theoretical enhancement was within 1 order of magnitude of the experimental observations (i.e., deviations of up to 10 dB). The duration of contrast enhancement was 1-2 min for air-filled bubbles, 3-5 min for SF6-filled bubbles and more than 7 min for C4F10-filled bubbles. In conclusion, ST68-SF6 microbubbles produced most in vivo enhancement of the agent/gas combinations studied. Theory matched the measurements within an order of magnitude.

Non-invasive diagnosis of hepatic cirrhosis by transit-time analysis of an ultrasound contrast agent

BACKGROUND

Hepatic cirrhosis is accompanied by several haemodynamic changes including arterialisation of the liver, intrahepatic shunts, pulmonary arteriovenous shunts, and a hyperdynamic circulatory state. We postulated that the hepatic first pass of a bolus of an ultrasound contrast agent injected into a peripheral vein is accelerated in patients with cirrhosis. We investigated this first pass in patients with diffuse liver disease and in normal controls to assess whether it provides useful differential diagnostic information.

METHODS

We enrolled 15 patients with biopsy-proven cirrhosis, 12 patients with biopsy-proven non-cirrhotic diffuse liver disease, and 11 normal controls. We carried out continuous spectral doppler ultrasonography of a hepatic vein from 20 s before to 3 min after a peripheral intravenous bolus injection of 2.5 g Levovist. The intensity of the doppler signal was measured and used to plot time-intensity curves.

FINDINGS

Patients with cirrhosis showed a much earlier onset of enhancement (arrival time; mean 18.3 s) and peak enhancement (mean 55.5 s) than controls (49.8 s and 97.5 s) or patients with non-cirrhotic diffuse liver disease (35.8 s and 79.7 s). All patients with cirrhosis had an arrival time of the bolus of less than 24 s, whereas the arrival time was 24 s or more in 22 of the 23 other participants. Peak enhancement was higher in patients with cirrhosis (mean 48.7 units) than in the other two groups (12.5 and 12.3 units, respectively). We found highly significant differences between the patients with cirrhosis and each of the other two groups for all variables (p<0.005), whereas we found no significant differences between non-cirrhotic patients and controls.

INTERPRETATION

Our preliminary study suggests that analysis of liver transit time of a bolus of ultrasound contrast agent provides useful information about haemodynamic changes in patients with cirrhosis. Measurement of the arrival time of the bolus allows discrimination of patients with cirrhosis from controls and from patients with non-cirrhotic diffuse liver disease, and has potential as a non-invasive test for cirrhosis.

A mathematical model for the assessment of hemodynamic parameters using quantitative contrast echocardiography

A mathematical model for the assessment of hemodynamic parameters using quantitative echocardiography is presented. The method involves the intravenous injection of an ultrasonic echo contrast agent. The relative enhancement of the backscattered ultrasound intensity is measured as a function of time (the time-intensity curve). From this measurement, the volume flow rate (cardiac output) and the mixing volume are calculated. Relevant acoustic properties of the ultrasound contrast agent are discussed. An in vitro experiment is performed to corroborate the theory presented.

Methods for quantifying ultrasound backscatter and two-dimensional video intensity: implications for contrast-enhanced sonography

Quantification of acoustic backscatter energy is believed to be useful for assessing "tissue character" and for quantifying the regional concentration of echo contrast. Measurement of ultrasonic video intensity has been the traditional means of quantifying backscatter energy, with "integrated backscatter" considered the gold standard. The purpose of this work is to review the commonly used methods for quantifying ultrasonic backscatter and to describe the difference between detected backscatter energy and the intrinsic tissue backscatter coefficient. Many of the quantification pitfalls that can lead to erroneous conclusions will also be discussed. A set of eight rubber phantoms with backscatter coefficient from -6 dB to +15 dB relative to liver were imaged at 2.5, 3.5, and 5.0 MHz. Methods for calculating the acoustic backscatter intensity from calibrated video intensity measurements and for calculating the tissue backscatter coefficient are described and tested using equipment from two different manufacturers. A commercially available automatic "acoustic densitometry" system with on-board quantitative integrated backscatter is also evaluated. Ultrasound attenuation and ultrasound system factors were found to strongly influence the detected backscatter intensity using either calibrated video intensity or on-board integrated backscatter. Special system transfer functions and attenuation correction were found to be useful in converting video intensity and integrated backscatter to a measure of the intrinsic tissue backscatter coefficient. With these correction factors, the correlation between the measured tissue backscatter coefficient and the phantom backscatter coefficient was excellent (r = 0.99, intercept 0.0, regression slope essentially 1.0) at all three imaging frequencies with traditional video intensity or on-board integrated backscatter. Uncalibrated video intensity and on-board integrated backscatter have limitations when used in isolation for tissue characterization. Rigorous attention to the imaging parameters and the use of calibration functions are necessary before video intensity measurement or integrated backscatter can be used reliably to measure the tissue backscatter coefficient.

Quantitative acoustic characterization of a new surfactant-based ultrasound contrast agent

The acoustic properties of a new ultrasound contrast agent, ST68, have been investigated. ST68 is a sonicated mixture of nonionic surfactants (Span-type and Tween-type) consisting of stabilized microbubbles with a mean diameter of 3.8 microns and a concentrations of 7.1 x 10(8) bubbles/mL. A pulsatile flow system was used to acquire data in vitro. The acoustic properties of ST68, as a function of time, frequency and dose, were calculated. Enhancement changed nonlinearly with contrast agent dose; maximum was 13.1 dB +/- 1.0 dB for a dose of 0.30 microL/mL of suspending medium. Attenuation reached approximately 11 dB/cm for dosages above 0.27 microL/mL and for frequencies between 2.5 and 6.0 MHz. In vivo, i.v. injections of ST68 were given to 4 rabbits (doses from 0.01 to 0.23 mL/kg). A clear increase in flow signal intensity was observed for 1 to 2 min. An in vivo dose-response curve was calculated from audio Doppler signals obtained with a 10-MHz cuff transducer placed around the distal aorta. Maximum enhancement was 18.3 dB +/- 3.13 dB for a 0.13 mL/kg dose. Moreover, ST68 appears to follow a simple relationship between in vivo enhancement and dose. In conclusion, ST68 is capable of producing marked vascular enhancement. Its acoustic properties have been characterized in vitro and in vivo.

Harmonic imaging with Levovist

Our purpose was to test the hypothesis that second harmonic imaging preferentially detects backscatter from microbubbles compared with tissue structural components. A prototype second harmonic scanner was used to image a flow channel in a tissue-mimicking rubber phantom (liver density). Video time-intensity curves were calculated from repeated bolus injections of microbubble echocardiographic contrast material under the same fluid dynamic conditions but with three different imaging modes: (1) fundamental imaging at 2.5 MHz (transmit and receive at 2.5 MHz), (2) fun damental imaging at 5.0 MHz (transmit and receive at 5.0 MHz), and (3) second harmonic imaging (transmit at 2.5 MHz and receive at 5.0 MHz). Each video time-intensity curve was calibrated-such that quantitative backscatter intensity was measured relative to the tissue phantom (0 dB). The peak increase in backscatter from the contrast material in the channel relative to the tissue phantom and the intensity in the channel before the contrast effect (the noise floor) was measured along with the area under the calibrated time-intensity curve relative to the phantom. When referenced to the noise floor in the flow channel, all imaging modes produced approximately 25 dB of enhancement. However, when referenced to the tissue phantom, second harmonic imaging produced a 22.3 +/- 1.8 dB peak enhancement, which was greater than either fundamental imaging at 2.5 MHz (15.5 +/- 0.8 dB; p < 0.001) or fundamental imaging at 5.0 MHz (15.3 +/- 1.5 dB; p < 0.001). The area under the time-intensity curves confirmed that harmonic imaging has approximately 7 dB of relative enhancement to the phantom compared with fundamental imaging at either frequency. Second harmonic imaging specifically enhances backscatter from microbubbles compared with a tissue-mimicking phantom. This specificity for microbubbles is due to a decrease in backscatter for the tissue phantom, rather than an increase in backscatter for the microbubbles. These data support the hypothesis that second harmonic imaging may be able to detect microbubbles in the tissue vascular space by preferentially decreasing the backscatter from tissue structural components.

The Doppler kinetics of microbubble echo contrast

The right and left heart kinetics of a saccharide-based microbubble echo contrast agent were measured in 11 anesthetized dogs using Doppler intensity as a measure of microbubble concentration while controlling for the dose administered, weight of the subject and cardiac output. A two-phase Doppler time-intensity curve was noted in all vascular regions. A brief first pass effect (phase 1) was found to depend on the contrast dose, cardiac output and subject size. This was followed by a much longer nearly steady-state elevation in the Doppler intensity compared with baseline (phase 2). The kinetics of phase 2 were found to be the same in all vascular distributions and independent of cardiac output. The phase 2 kinetics depend on the contrast dose, subject size and elimination characteristics of the contrast agent. The clinically important conclusions are: (1) the magnitude of Doppler enhancement and duration of the contrast effect can be predicted using the simple formulas presented; (2) the flow-dependent portion of the arterial contrast effect is effectively over only a few seconds after intravenous injection; and (3) the kinetics of phase 2 are the same throughout the body.

When can Doppler be used in place of integrated backscatter as a measure of scattered ultrasound intensity?

The purpose of this work was to determine under what circumstances the intensity of Doppler audio signals can be used as a substitute for the more direct and complex measure of ultrasonic backscatter (integrated backscatter) which requires radio-frequency ultrasound signals. Using a rotating rubber disk phantom and a microbubble echo-contrast flow phantom, we have shown that the intensity of audio Doppler signals is independent of the constraints typically associated with Doppler ultrasound (velocity and angle), but like integrated backscatter depends on the transmit intensity, gain of the ultrasound receiver, attenuation and the nature of the scatterers. Using Doppler ultrasound for backscatter measurements is ideally suited for the expected application of the technique: the assessment of echo contrast in cardiac chambers, blood vessels and tissue perfusion (i.e., any flow system). Compared to integrated backscatter, the Doppler audio method has the advantage of using standard clinical ultrasound machines, requires less sophisticated data storage and processing equipment and the positioning system for the region of interest (the Doppler sample volume) is built into all pulsed-wave Doppler machines. Further, the low-velocity filter removes all nonmoving scatterers (like the intense echoes from heart valves and the walls of blood vessels), thus allowing study of only those echoes originating from the blood pool. This combination of features is what attracted us to the Doppler method for quantitating ultrasonic backscatter in flow systems.

Ultrasound contrast agents: a review

During the past 25 years, many attempts have been made to establish effective ultrasound contrast agents for both cardiac and noncardiac applications. The ideal ultrasound contrast agent would be: (a) nontoxic; (b) injectable intravenously; (c) capable of passing through the pulmonary, cardiac and capillary circulations; and (d) stable for recirculation. A variety of potential ultrasound contrast agents have been or are now under development. Present and future ultrasound contrast agents should provide for increased diagnostic capabilities in a variety of normal and abnormal vessels and organs throughout the body. These agents will enhance tumor vascularity, delineate areas of ischemia, as well as improve visualization of vascular stenosis. Future developments with modification of ultrasound equipment should increase the capabilities of these agents to improve imaging as well as Doppler sensitivity.